KOL Perspectives: Treatment strategies for pregnant RA patients
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Questions topics:
› Current views on suitable therapies to treat pregnant RA patients
› Certolizumab –use in pregnant RA patients
› Other anti-TNFs –use in pregnant RA patients
› IL-6 inhibitors –use in pregnant RA patients
› Abatacept –use in pregnant RA patients
› JAK inhibitors –use in pregnant RA patients
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during Apr 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Majority of KOLs currently use anti-TNFs for treating pregnant RA patients, with a marked preference for certolizumab
No consensus among KOLs on the use of IL-6 inhibitors during pregnancy, although monotherapy use was not considered an advantage
Majority of KOLs were averse to prescribing JAK inhibitors during pregnancy, primarily due to the lack of any data in this setting
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on Treatment strategies for pregnant RA patients
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Immunology reports